- Cagrilintide/GLP-1 (Sema) is a combination peptide formulation designed for investigative use in metabolic and appetite regulation research models. This dual-agent compound includes both a long-acting amylin analog (Cagrilintide) and a GLP-1 (Sema) receptor agonist, facilitating synergistic modulation of satiety and glycemic pathways in preclinical settings.
- This formulation has been studied for its effects on energy homeostasis, gastric emptying, and appetite signaling, offering valuable insights into complex neuroendocrine mechanisms governing caloric intake and metabolic balance.
- Research indicates that the Cagrilintide/GLP-1 (Sema) combination may enhance experimental outcomes in obesity and diabetes models by promoting sustained reductions in food intake and improvements in glucose tolerance.
- Investigators have explored this peptide pairing for its potential to influence body weight regulation, insulin sensitivity, and lipid profiles in animal and cellular models, making it a promising candidate for advanced metabolic research protocols.
- Cagrilintide/GLP-1 (Sema) (5mg/5mg) is intended for laboratory research use only. This compound is ideal for institutions conducting studies on appetite regulation, metabolic disorders, and endocrine signaling.
Age Verification
You must be at least 21 years old to enter this website. All products are for laboratory research use only and are not for human or animal consumption.